 To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor statin therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patients cardiovascular risks are assessed to determine if National Cholesterol Education Programs Adult Treatment Panel III NCEP ATP III guidelines for low density lipoprotein LDL reduction were achieved between the three groups. Secondary measures examine the safety issues with liver function test LFT monitoring and rhabdomyolysis. High-density lipoproteins HDL elevations are monitored between the three groups to determine efficacy as a secondary outcome. 